PROTOCOL SPECIFIC RESEARCH SUPPORT

特定于协议的研究支持

基本信息

批准号：
7944582
负责人：
FRANK L. MEYSKENS
金额：
$ 4.78万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-06 至 2012-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7944582
关键词：
Accounting Address Applications Grants Area CCI-779 Cancer Center Cancer Center Support Grant Capital Categories Characteristics Chronic Myeloid Leukemia Clinical Clinical Research Clinical Trials Clinical Trials Design Clinical trial protocol document Data Detection Development Devices Diagnosis Disease Double-Blind Method Ensure Erlotinib Extramural Activities Faculty Fostering Foundations Funding Future Goals Grant Guidelines Gynecologic Oncology Gynecologic Oncology Group Head Human Resources Imatinib mesylate Industry Intervention Intervention Trial Lovastatin Malignant Neoplasms Monitor Mucinous Neoplasm Names National Cancer Institute Nursing Research Pancreas Patients Peer Review Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Phase III Clinical Trials Physicians Placebo Control Policies Prevention Protocols documentation Qualifying Randomized Reporting Research Research Personnel Research Support Resources Scientist Source Southwest Oncology Group Strategic Planning Testing Therapeutic Therapy Clinical Trials Translational Research Translations United States National Institutes of Health University of California Irvine Cancer Center Work base cancer therapy data management innovation melanoma member novel preference programs protocol development success

项目摘要

9.3 Protocol-Specific Research Support (locally named Protocol-Specific Data Management) In accordance with the National Cancer Institute Policies and Guidelines Relating to the Cancer Center Support Grant, this core group of research nurses and data managers provides central management and oversight functions for coordinating, facilitating and reporting on the cancer clinical trials of the Cancer Center. Of primary importance is the identification and support of phase I and II trials emanating from the work generated by Cancer Center affiliated physician-scientists. Support is prioritized to ensure the initiation and completion of innovative, feasibility, or proof-of-principle clinical trials originating from the Center's Programs and of highest priority to the Center. These include any kind of clinical translational research culminating in the initial early-phase testing of a candidate agent or device for the diagnosis, prevention, detection, or treatment of cancer. The ultimate goal of supporting such research efforts is to foster the translation of feasibility/phase I studies into future grant applications or into phase II and phase III studies supported by NCI or industry. Oversight of this group is provided by the Associate Director of Clinical Research.

9.3特定于协议的研究支持（本地命名的特定于协议的数据管理）根据国家癌症研究所的政策和与癌症中心有关的准则支持赠款，这一核心研究护士和数据经理提供了中央管理和监督功能，用于协调，促进和报告癌症的癌症临床试验中心。最重要的是对I期和II期试验的识别和支持癌症中心附属医师科学家产生的工作。优先考虑支持以确保启动并完成源自该中心的创新，可行性或原则临床试验程序和最高优先级的中心。这些包括任何类型的临床翻译研究最终在候选剂或设备的初始早期测试中进行诊断，预防，检测或治疗癌症。支持此类研究工作的最终目标是促进将可行性/I期研究转换为未来的赠款应用或II期和第三阶段研究由NCI或行业支持。该组的监督由临床副主任提供研究。